

immuron

JUNE 2024 NEWSLETTER





Global

- FYTD Mar 2024 AUD\$3.6 million up 154% on (prior comparative period) pcp
- Mar 2024 Quarter AUD\$1.3 million up 51% on pcp and 75% on last quarter



Business Update

- Flagship product, Travelan®, growing strongly as overseas travel rebounds
- Travelan® (IMM-124E) Phase 2 CHIM trial topline results
- Travelan® (IMM-124E) Travelan® Uniformed Services University (USU) P2TD IMM-124E field clinical trial recruited ~75% of target 866
- CampETEC Phase 2 clinical trial completed inpatient phase

immuron RECENT NEWS

Travelan to Progress to Phase 3 Clinical Trials in the U.S.



Appointment of Dr Jeannie Joughin as a Non-Executive Director



Immuron Record Sales Achieved January 2024

Clinical Trials Update December 2023

Resignation of Non-Executive Directors: Stephen Anastasiou and Roger Aston

Analyst Reports 1H 2024

WHERE TO BUY TRAVELAN







immuron IN THE MEDIA

Biotech Daily: Dr Boreham's Crucible: Immuron

May 10, 2024

Immuron is in the throes of multiple clinical trials - one of them on the cusp of phase III - to prove the efficacy of Travelan against specific diarrhoea-inducing pathogens.



[Click Here for More](#)

The Watchlist: Immuron's Travelan sales growth, clinical pipeline achievements and upcoming milestones!

April 26, 2024

CEO Steve Lydeamore provides an update on Travelan's exponential growth!



[Click Here for More](#)

Immuron marks surge in Travelan® sales on eve of entry into US via Walmart.com

April 10, 2024

Immuron Ltd (NASDAQ:IMRN, ASX:IMC), a biopharmaceutical company headquartered in Australia, says sales of its immune supplement Travelan® have soared.



[Click Here for More](#)

Guarding Gut Health on the Go: The Travelan® Advantage

April 10, 2024

The Not Old Better Show, Art of Living Interview Series. Today's episode takes us on a fascinating journey through the landscape of travel health, an essential yet often overlooked aspect of our adventures abroad.



[Click Here for More](#)

Immuron (ASX:IMC): Clinical data imminent!

February 6, 2024

We spoke to Immuron CEO Steve Lydeamore about the clinical work it is doing with IMM-124e and IMM-529, its involvement with the Uniformed Services University and the Naval Medical Research Command, and the commercial opportunity for Travelan now that people are travelling again.



[Click Here for More](#)

Beating bacteria just got boosted

November 11, 2023

We might like experiencing new places, but our tummies don't always agree with us. Here's something that might suit some. Travelan is an immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal tract.



[Click Here for More](#)

Immuron hails record monthly sales of Travelan

September 18, 2023

Immuron Ltd (NASDAQ:IMRN, ASX:IMC) CEO Steve Lydeamore speaks with Proactive following news the company has achieved record monthly sales of its over-the-counter gastrointestinal supplement Travelan®.



[Click Here for More](#)

Email Sign Up!

Immuron Investor Center



Immuron, Ltd. | Building 10, 25-37 Chapman Street Blackburn North, VIC | Australia, State/Province 31131 AU

[Unsubscribe](#) | [Update Profile](#) | [Constant Contact Data Notice](#)